$251 Million is the total value of Clarus Ventures, LLC's 6 reported holdings in Q3 2014. The portfolio turnover from Q2 2014 to Q3 2014 was 20.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
AERI | Aerie Pharmaceuticals Inc. | $71,763,000 | -16.5% | 3,468,495 | 0.0% | 28.64% | -6.1% | |
OPHT | Ophthotech Corp | $60,526,000 | -8.0% | 1,554,744 | 0.0% | 24.15% | +3.4% | |
NSTG | Nanostring Technologies Inc. | $43,316,000 | -26.8% | 3,959,440 | 0.0% | 17.28% | -17.8% | |
OXFD | Oxford Immunotec Global PLC | $39,382,000 | -9.3% | 2,579,062 | 0.0% | 15.71% | +2.0% | |
TLOG | TetraLogic Pharmaceuticals Corporation | $19,322,000 | -29.4% | 4,644,705 | 0.0% | 7.71% | -20.6% | |
VBIV | New | VBI Vaccines Inc | $16,305,000 | – | 4,971,091 | +100.0% | 6.51% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-11-13
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
Nanostring Technologies Inc. | 20 | Q3 2018 | 60.2% |
Sientra Inc. | 16 | Q3 2018 | 38.2% |
Oxford Immunotex Global PLC | 14 | Q1 2017 | 17.4% |
Catabasis Pharmaceuticals Inc. | 14 | Q3 2018 | 15.3% |
VBI Vaccines Inc. | 10 | Q3 2018 | 11.4% |
TetraLogic Pharmaceuticals Corporation | 9 | Q4 2015 | 12.5% |
ESSA Pharma Inc. | 9 | Q1 2018 | 6.5% |
Aerie Pharmaceuticals Inc. | 7 | Q4 2015 | 30.5% |
VBI Vaccines Inc. | 7 | Q1 2016 | 9.1% |
Ophthotech Corp | 6 | Q1 2015 | 31.5% |
View Clarus Ventures, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-NT | 2024-05-15 |
13F-NT | 2024-02-14 |
13F-NT | 2023-11-14 |
13F-NT | 2023-08-14 |
13F-NT | 2023-05-15 |
13F-NT | 2023-02-14 |
13F-NT | 2022-11-14 |
13F-NT | 2022-08-15 |
13F-NT | 2022-05-16 |
13F-NT | 2022-02-14 |
View Clarus Ventures, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.